Head and Neck Squamous Cell Carcinoma
Pipeline by Development Stage
Drug Modality Breakdown
Head and Neck Squamous Cell Carcinoma is a $5.3B market in mature consolidation, dominated by off-label use of multi-indication therapies rather than HNSCC-specific treatments.
Key Trends
- Market driven almost entirely by secondary indication use (100% of top 10 products are off-label)
- Kinase inhibitors and PARPi dominate; immunotherapy has limited penetration despite clinical rationale
- Heavy patent cliff pressure in 2028-2033 window threatens market stability
Career Verdict
Proceed with caution: the market lacks primary indication focus, meaning career advancement may be limited by label restrictions and competition from larger oncology franchises.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | JAKAFI (Ruxolitinib) | Incyte | $1.9B | 36% | LOE_APPROACHING | Declining | 2.5yr |
| 2 | CABOMETYX (Cabozantinib) | Exelixis | $1.1B | 21% | PEAK | Stable | 7.1yr |
| 3 | VERZENIO (Abemaciclib) | Eli Lilly and Company | $757M | 14% | PEAK | Stable | 5.3yr |
| 4 | LYNPARZA (Olaparib) | AstraZeneca | $487M | 9% | PEAK | Stable | 5.1yr |
| 5 | KEYTRUDA (Pembrolizumab) | Merck & Co. | $117M | 2% | PEAK | Stable |
Drug Class Breakdown
declining (patent cliff 2028)
stable through 2033
stable
stable
stable; limited uptake
heterogeneous
Career Outlook
StableHNSCC represents a stable but non-differentiated segment within broader oncology portfolios. The market is mature and driven by secondary indications, meaning career progression depends on success of parent oncology franchises (LYNPARZA, CABOMETYX, KEYTRUDA) rather than HNSCC-specific innovation. Patent cliff pressure in 2028-2033 will force portfolio restructuring, creating near-term vulnerability for specialists.
Breaking In
Target larger pharma (AstraZeneca, Takeda, Bristol Myers Squibb) where HNSCC is part of a diversified oncology portfolio; expect rotation across multiple cancer types rather than deep HNSCC focus.
For Experienced Professionals
If already oncology-specialized, HNSCC roles offer lateral moves but limited upside; prioritize companies with primary-indication HNSCC programs or strong immunotherapy pipelines (Merck, Bristol Myers Squibb) for future-proofing.
In-Demand Skills
Best For
Hiring Landscape
4,663 total jobs available across 15 companies, with hiring concentrated in Commercial (782 roles, $246K avg) and Medical Affairs (264 roles, $333K avg). AstraZeneca and Takeda lead hiring (1,141 and 1,106 roles respectively), reflecting portfolio breadth rather than HNSCC-specific demand. Salary range spans $182K-$333K depending on department.
Top Hiring Companies
By Department
Hiring is robust but generalist in nature; HNSCC specialists will compete within larger oncology teams, limiting visibility and specialized career paths.
On Market (1)
Approved therapies currently available
Competitive Landscape
57 companies ranked by most advanced pipeline stage
+27 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 7,230 patients across 50 trials
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma
Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN)
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)
Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck
Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy
Gabapentin With or Without Antidepressants in Treating Hot Flashes in Women Who Have Had Breast Cancer or Have Concerns About Taking Hormone Therapy
Gabapentin in Treating Peripheral Neuropathy in Cancer Patients Undergoing Chemotherapy
Gabapentin in Treating Hot Flashes in Patients With Prostate Cancer
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.
CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs
Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC
A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)
FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma
Dose Escalation Using Hypoxia-adjusted Radiotherapy
Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).
Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer
A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC
SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.
SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.
SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies
A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC
Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab
MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients
Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca
Ruxolitinib in Operable Head and Neck Cancer
A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
Pembrolizumab in HNSCC With Residual Disease After Radiation
Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer
Study of SCB01A in Patient With Head and Neck Cancer
Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy
Oral Rigosertib for Squamous Cell Carcinoma
Preoperative Treatment With Cetuximab and/or IMC-A12
Pazopanib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Docetaxel and S-1 in Head and Neck Squamous Cell Carcinoma (HNSCC)
Comparison of Aprepitant Versus Gabapentin in the Prevention of Delayed Nausea and Vomiting
Related Jobs in Oncology
Customer Service Representative
Sr. Account Manager - Molecular Instruments
Area Sales Manager
Data & AI Product Owner – Quality
Manufacturing Technician II, POROS Manufacturing (Rotating Weekends, Day Shift)
Sr QC Technician
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.